Immuno-Biological LaboratoriesImmuno-Biological Laboratories Co., Ltd.4570東証グロース医薬品FY ending Mar 2026, consolidated, J-GAAP
Out of every ¥100 of sales, about ¥28 is left as operating profit. Revenue changed +3.7% from the prior year, operating profit +34.4%.
Net margin × asset turnover = ROA; ROA × financial leverage = ROE
Denominators: average assets and average equity. Derived from reported values; ROE is shown only for positive profit and equity.
| Period | Net margin | Asset turnover | ROA | Financial leverage | ROE |
|---|---|---|---|---|---|
| 2022 | — | —× | -15.2% | —× | — |
| 2023 | — | —× | -18.5% | —× | — |
| 2024 | 22.9% | 0.54× | 12.2% | 1.30× | 15.9% |
| 2025 | 25.7% | 0.56× | 14.4% | 1.25× | 17.9% |
| 2026 | 32.7% | 0.50× | 16.4% | 1.19× | 19.6% |
Financial leverage can raise ROE; a higher value alone does not describe a company's overall condition.
Annual trends in tangible-asset ratios and goodwill balance.
Ratios are derived from reported values. Goodwill is shown only when separately reported; it is not inferred from combined intangible assets. Definition
Track R&D investment and how long operating capital remains tied up before sales turn into cash.
R&D is shown only for years with machine-readable disclosure. Days are estimates using year-end receivables, inventory and payables divided by annual revenue or cost of sales; financial companies are excluded.
| Item | FY ending Mar 2022 | FY ending Mar 2023 | FY ending Mar 2024 | FY ending Mar 2025 | FY ending Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 648 | 795 | 817 | 970 | 1,005 |
| Cost of revenue | 271 | 268 | 299 | 335 | 298 |
| Gross profit | 377 | 527 | 517 | 634 | 707 |
| SG&A | 499 | 470 | 413 | 425 | 426 |
| Operating income | -122 | 57 | 104 | 209 | 281 |
| Pretax income | -250 | -281 | 125 | 210 | 301 |
| Income tax | 9 | 9 | -62 | -39 | -28 |
| Net income attributable to owners | -259 | -290 | 187 | 249 | 329 |
| Operating margin | -18.9% | 7.2% | 12.8% | 21.6% | 28.0% |
Year-end figures from filings. Unreported items are omitted. Interest-bearing debt excludes lease liabilities.
Each bar totals 100% of assets; other is the residual.
| Item | FY ending Mar 2022 | FY ending Mar 2023 | FY ending Mar 2024 | FY ending Mar 2025 | FY ending Mar 2026 |
|---|---|---|---|---|---|
| Cash and equivalents | ¥449.2M | ¥562M | ¥675M | ¥770.6M | ¥928.3M |
| Total assets | ¥1.71B | ¥1.43B | ¥1.62B | ¥1.85B | ¥2.16B |
| Net assets | ¥1.37B | ¥1.08B | ¥1.27B | ¥1.51B | ¥1.84B |
| Share capital | ¥3.03B | ¥3.03B | ¥50M | ¥50M | ¥50M |
| Property, plant and equipment | ¥120.1M | ¥119.3M | ¥135.8M | ¥191.1M | ¥213.2M |
| Intangible assets excluding goodwill | — | — | ¥2.3M | ¥1.8M | ¥1.3M |
| Investment securities | ¥399.8M | ¥95.2M | ¥95.1M | ¥95.1M | ¥170.1M |
| Current assets | ¥1.13B | ¥1.17B | ¥1.26B | ¥1.39B | ¥1.57B |
| Current liabilities | ¥228.1M | ¥252M | ¥257.8M | ¥281.3M | ¥276.2M |
| Trade payables | ¥3.9M | ¥5.7M | ¥4.3M | ¥3.7M | ¥3M |
| Short-term borrowings | ¥125M | ¥130M | ¥135M | ¥140M | ¥142M |
| Long-term borrowings | ¥105M | ¥99.1M | ¥84.6M | ¥35.1M | ¥18.7M |
| Total liabilities | ¥337M | ¥355.7M | ¥353.3M | ¥331M | ¥311.7M |
| Equity attributable to owners of parent | ¥1.37B | ¥1.08B | ¥1.27B | ¥1.51B | ¥1.84B |
| Retained earnings | -¥3.72B | -¥4.01B | ¥176.9M | ¥425.9M | ¥755M |
| Treasury stock | -¥2M | -¥2M | -¥2M | -¥2M | -¥2M |
EDINET (FSA Japan)
有価証券報告書－第44期(2025/04/01－2026/03/31)
EDINET (FSA Japan)
有価証券報告書－第43期(2024/04/01－2025/03/31)
EDINET (FSA Japan)
有価証券報告書－第42期(2023/04/01－2024/03/31)
EDINET (FSA Japan)
有価証券報告書－第41期(2022/04/01－2023/03/31)
EDINET (FSA Japan)
有価証券報告書－第40期(令和3年4月1日－令和4年3月31日)
EDINET (FSA Japan)
訂正有価証券報告書－第39期(令和2年4月1日－令和3年3月31日)
Extracted from XBRL: 46 / Derived from other figures: 1
Spotted an error? Report it (corrections keep the original record)
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.